Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer
Conditions
Brief summary
Success of cancer immunotherapy is limited by the ability of solid tumors to evade local and systemic antitumoral immune responses. Several mechanisms of tumor immune evasion have been identified, including low intratumor expression of antigens and elevated expression of inhibitory co-regulatory molecules. An effective immunotherapy is one which would induce necrotic cell death and accompanying proinflammatory cytokine induction. Stereotactic Body Radiotherapy (SBRT) or Intensity Modulated Radiotherapy (IMRT) or brachytherapy, which is capable of delivering high, conformal radiation doses (\>8 Gy) of tumor ablative radiation may be an effective means of conditioning a tumor bed to a state favorable to the initiation of robust antitumoral immune responses.
Interventions
RADIATIONSBRT
RADIATIONIMRT
RADIATIONBrachytherapy
Sponsors
Mayo Clinic
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Hormone Refractory, Metastatic Prostate Cancer, Lung Cancer, and Melanoma or Breast Cancer
Exclusion criteria
-Life expectancy of less than 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in immune biomarkers from baseline and after radiation treatments for breast, prostate, and lung cancers. | Before and after SBRT, IMRT, or brachytherapy | Changes in baseline circulating tumor reactive immune markers after radiotherapy. |
Countries
United States
Outcome results
None listed